176
Views
10
CrossRef citations to date
0
Altmetric
BRIEF REPORT Hematologic Complications Related to Infections

Management of Severe Refractory Thrombocytopenia in Dengue Hemorrhagic Fever With Intravenous Anti-D Immune Globulin

, DNB, , DNB, , DNB & , MD
Pages 727-732 | Received 17 Apr 2011, Accepted 28 Jul 2011, Published online: 04 Oct 2011

REFERENCES

  • Gubler DJ, Clark GG. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis. 1995;1:55–57.
  • WHO. Dengue and Dengue Haemorrhagic Fever. Fact Sheet No. 117, revised May 2008. Geneva: World Health Organization; 2008.
  • Nimmannitya S. Dengue hemorrhagic fever: disorders of hemostasis. In: Education Book, IX Congress of the International Society of Haematology Asia-Pacific Division; Bangkok; October 24–28, 1999. International Society of Haematology, Asia-Pacific Division, pp. 184–187.
  • Saito M, Oishi K, Inoue S, Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections. Clin Exp Immunol. 2004;138:299–303.
  • Mitrakul C. Hemostatic and platelet kinetic studies in dengue hemorrhagic fever. Am J Trop Med Hyg. 1979;26:975–984.
  • Boonpucknavig S. Demonstration of dengue antibody complexes on the surface of platelets from patients with dengue hemorrhagic fever. Am J Trop Med Hyg. 1979;28:881–884.
  • McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1981;304:1135–1147.
  • Cines DB. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995–1008.
  • Muller-Eckhardt C. The clinical significance of platelet associated IgG: a study on 298 patients with various disorders. Br J Haematol. 1980;46:123–131.
  • Kularante SAM, Walathara C, Mahindawansa SI, Efficacy of low dose dexamethasone in severe thrombocytopenia caused by dengue fever: a placebo controlled study. Postgrad Med J. 2009;85:525–529.
  • Dimaano ME, Saito M, Honda S, Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. Am J Trop Med Hyg. 2007;77:1135–1138.
  • Yadav SP. What else can be done other than vector control to reduce mortality due to Dengue hemorrhagic fever (DHF)? BMJ. 2006. Available at: http://www.bmj.com/content/333/7572/773.4/reply.
  • De Castro RA, de Castro JA, Barez MY, Thrombocytopenia associated with dengue hemorrhagic fever responds to intravenous administration anti D (Rh-D) antiglobulin. Am J Trop Med Hyg. 2007;76:737–742.
  • Yadav SP, Sachdeva A, Kharya G, Control of massive bleeding in dengue hemorrhagic fever with severe thrombocytopenia by use of intravenous anti-D globulin. Pediatr Blood Cancer. 2008;51:812–813.
  • British Committee for Standards in Haematology. Guidelines for the use of Platelet Transfusions. Br J Haematol. 2003;122:10–23.
  • Makroo RN, Raina V, Kumar P, Role of platelet transfusion in the management of dengue patients in a tertiary care hospital. Am J Transf Sci. 2007;1:4–7.
  • Scaradavou A, Woo B, Woloski BM, Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997;89:2689–2700.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.